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Abstract
Human cancers often contain genetic alterations that disable G1/S checkpoint control and loss of this checkpoint is thought
to critically contribute to cancer generation by permitting inappropriate proliferation and distorting fate-driven cell cycle
exit. The identification of cell permeable small molecules that activate the G1/S checkpoint may therefore represent a
broadly applicable and clinically effective strategy for the treatment of cancer. Here we describe the identification of several
novel small molecules that trigger G1/S checkpoint activation and characterise the mechanism of action for one,
CCT020312, in detail. Transcriptional profiling by cDNA microarray combined with reverse genetics revealed
phosphorylation of the eukaryotic initiation factor 2-alpha (EIF2A) through the eukaryotic translation initiation factor 2-
alpha kinase 3 (EIF2AK3/PERK) as the mechanism of action of this compound. While EIF2AK3/PERK activation classically
follows endoplasmic reticulum (ER) stress signalling that sets off a range of different cellular responses, CCT020312 does not
trigger these other cellular responses but instead selectively elicits EIF2AK3/PERK signalling. Phosphorylation of EIF2A by
EIF2A kinases is a known means to block protein translation and hence restriction point transit in G1, but further supports
apoptosis in specific contexts. Significantly, EIF2AK3/PERK signalling has previously been linked to the resistance of cancer
cells to multiple anticancer chemotherapeutic agents, including drugs that target the ubiquitin/proteasome pathway and
taxanes. Consistent with such findings CCT020312 sensitizes cancer cells with defective taxane-induced EIF2A
phosphorylation to paclitaxel treatment. Our work therefore identifies CCT020312 as a novel small molecule chemical
tool for the selective activation of EIF2A-mediated translation control with utility for proof-of-concept applications in EIF2A-
centered therapeutic approaches, and as a chemical starting point for pathway selective agent development. We
demonstrate that consistent with its mode of action CCT020312 is capable of delivering potent, and EIF2AK3 selective,
proliferation control and can act as a sensitizer to chemotherapy-associated stresses as elicited by taxanes.
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Introduction
G1/S checkpoint activation is recognized to play an important
role in tumour suppression [1]. The retinoblastoma tumour
suppressor protein (pRB) is a critical component in this checkpoint,
acting to inhibit the transcription of genes required for DNA
synthesis [2]. In addition, pRB prevents the degradation of the
cyclin dependent kinase inhibitors p21
CIP and p27
KIP1 by the Skp-
Cullin-F-box protein (SCF) ubiquitin ligase complex [3]. Phosphor-
ylation of pRB by the cyclin dependent kinases (CDK) 4 or 6 and
CDK2 inhibits these different activities of pRB, permitting transit of
cells into S-phase and facilitating DNA replication [4,5].
G1/S checkpoint control is impaired in the majority of cancers
[6,7]. Loss of control is caused by genetic alterations that affect the
functioning or expression of proteins that regulate the action of
pRB. Such alterations comprise inactivating mutations or gene loss
of the p16
INK4A CDK inhibitor, which inhibits the kinase activity
of CDK4 and 6 [8]; mutations in CDK4 or CDK6, rendering
these kinase catalytic subunits resistant to the action of INK4
family CDK inhibitors [9]; and the deregulated expression of D
cyclin genes, arising from either gene translocation [10,11] or,
more frequently, gene transcriptional activation as a consequence
of oncogene activation. Signalling through the Ras, wingless (Wnt)
and nuclear factor kappa B (NFkB) pathways all result in the
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activation of these pathways in cancers is thought to contribute
to unlicensed G1/S checkpoint transit [12,13].
Small molecule chemical probes represent important tools for
understanding cell pathways and validating potential therapeutic
approaches [14]. Identification of cell-permeable small molecules
that trigger the G1/S checkpoint through activation of pRB may
provide a promising avenue for reinstating proliferation control in
the clinical control of malignant disease.
Current efforts have primarily focussed on the catalytic
inhibition of the G1/S pRB-phosphorylating cyclin dependent
kinases CDK4 and CDK2 [15,16]. However, a considerable level
of functional redundancy appears to exist amongst members of this
kinase family, and a full complement of G1/S regulatory cyclin-
CDK complexes may be essential in some but not other cell types
[17,18], suggesting that effective checkpoint activation through
inhibition of these enzymes could be more problematic than
anticipated.
To identify agents and alternative targets capable of delivering
G1/S checkpoint activation, we undertook a mechanism-based
screen, scoring for the inhibition of pRB phosphorylation in
human cancer cells exposed to a library of small molecules. Here
we report identification and characterization of small molecule
agents that potently inhibit pRB phosphorylation and prolifera-
tion, amongst them a known kinase inhibitor with activity against
CDKs. We characterize in detail one compound, CCT020312,
which stood out using combined assessment of chemical properties
and biological effects. This compound does not inhibit CDKs but
leads to rapid loss of D cyclin expression, which we demonstrate
requires signalling through the eukaryotic initiation factor 2A
kinase 3 (EIF2AK3/PERK). It is known that EIF2AK3/PERK
activation is caused by agents that disable ER functioning, leading
to accumulation of unfolded proteins [19]. In contrast, we show
that CCT020312 does not elicit a generalized unfolded protein
response signal, but instead operates by a mechanism of action
that selectively boosts EIF2AK3/PERK signalling output.
Results
Identification of compounds leading to block of pRB
phosphorylation in cells
We used our previously described high-throughput assay to
identify agents capable of attenuating pRB phosphorylation in
proliferating HT29 human colon carcinoma cells [20], and
material and methods. HT29 cells were chosen for the screen
because they possess functional pRB but are deficient for the
tumour suppressor TP53 [21]. This eliminates identification of
undesired hits that act through TP53-mediated induction of the
CDK inhibitor p21
CIP1 and associated block of pRB phosphor-
ylation, which is common as a response to non-specific chemical
stress including chemically induced DNA damage. Hits in the
assay cause loss of Ser608-phosphorylation on human pRB (P-
S608-pRB), a known target of cyclin D-activated CDK4/6 [22].
Using this assay we screened the Cancer Therapeutics Unit
compound library of 63,000 chemically diverse compounds by
applying these at a concentration of 10 mM for 24 hours. A total of
53 compounds decreased the phospho-Ser608 pRB signal in
HT29 cells by greater than 50% compared to vehicle-treated
control, giving a screen hit rate of 0.08%. Eight of these hits were
reconfirmed as inhibitors of Ser608 phosphorylation of pRB by
western blot analysis (not shown).
Figure 1A shows the chemical structures of the eight confirmed
hits, arranged according to their potency for reducing the P-S608-
pRB signal. To further assess these eight hits we considered their
chemical properties (Figure 1B and Results S1) as well as biology-
led criteria (Figure 1B), including good correlation between
inhibition of pRB phosphorylation and growth inhibition,
suggesting that the latter is a consequence of the former. These
criteria favoured CCT039836 and CCT020312 (see Figure 1B)
and hence these were chosen for further characterization.
A search for prior art identified CCT039836 as a CDK
inhibitor [23] and our subsequent assessment showed half-
maximal inhibition of recombinant CDK4/cyclin D1 enzyme at
a concentration of 0.2 mM, with comparable potency against
recombinant G2/M kinase CDK1/cyclin B, (not shown).
Compounds with CDK inhibitory activity would be expected as
hits from a cell based screen using inhibition of pRB phosphor-
ylation as an endpoint, and identification of the known CDK
inhibitor CCT039836 provided assurance of assay performance.
In contrast, addition of CCT020312 to kinase reactions
containing CDK4/cyclin D or CDK1/cyclin B showed no effect
on the activity of these kinases at concentrations 10 times the EC50
for suppression of pRB phosphorylation in cellular assays (Figure
S1), nor did we find an effect on cyclin E- or cyclin A-activated
CDK2 (Figure S1). Inhibition of these kinases was seen in parallel
reactions containing the CDK inhibitors flavopiridol or R-
roscovitine (Figure S1). Therefore we concluded that
CCT020312 does not act through direct CDK inhibition.
Cellular effects of CCT020312
Treatment of HT29 cells with CCT020312 for 24 hours
revealed a concentration-dependent loss of P-S608-pRB signal,
with a linear response between 1.8 and 6.1 mM (Figure 2A).
Parallel assays in HCT116 colon carcinoma cells, revealed
inhibition of pRB phosphorylation at comparable concentrations
with half-maximal reduction of pRB phosphorylation at 4.2 and
5.7 mM in HT29 and HCT116 cells respectively (Figure S2).
These concentrations closely match those required for half-
maximal inhibition of growth (GI50) in these cell lines
(GI50=3.2 and 5.4 mM respectively) (Figure S2), in line with our
previous results obtained for the purpose of compound triage
(Figure 1B). Lastly, CCT020312 treatment effectively inhibited
cell proliferation (as measured at 96 hours) even if treatment was
for 2 hours only with subsequent compound washout, indicating
that CCT020312 is capable of eliciting durable rather than
transient cytostasis (Figure S2).
Flow-cytometry of HT29 cells exposed to 10 mM CCT020312
(Figure 2B) revealed an increased number of cells in the G1 phase
of the cell cycle at 16 and 24 hours as well as effective reduction of
DNA synthesis (Figure 2C), in agreement with the expectation that
loss of pRB phosphorylation results in blocking S phase entry.
Immunoblotting of cell lysates confirmed the presence of fast
migrating pRB in such cells and accumulation of a pRB species
specifically recognised by an antibody for the underphosphory-
lated active form of pRB, NP-pRB [22] (Figure 2D), indicating
that genuine activation of pRB signalling arises in CCT020312-
treated cancer cells.
To begin to uncover the molecular mechanism responsible for
the observed activation of pRB signalling and G1 arrest, we
examined the effect of CCT020312 on the expression of cell cycle
regulating proteins. Treatment of HT29 cells with 10 mM
CCT020312 for 24 hours reduced the amount of the G1/S
cyclins D1, D2, E and A as well as the CDK catalytic subunit
CDK2 and increased the level of the CDK inhibitor p27
KIP1
present in such cells (Figure 2E). The loss of D-type cyclins D1 and
D3 was readily detectable 120 min after treatment (Figure 2F),
coincident with the accumulation of underphosphorylated pRB,
indicating that cyclin D loss could be responsible for the
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and E and increased p27/KIP1 occurred later (Figure S3), and
thus may be consequence, rather than cause, of the inhibition of
pRB phosphorylation and G1/S transit. Cyclin D1 loss following
CCT020312 treatment was observed across a range of different
human cancer cell lines (Figure S3), including those known to
express aberrantly high amounts of this cyclin.
To determine the reason for the observed cyclin D1 loss we
probed for phosphorylation on Thr286 (Figure S4), which is
known to target this cyclin for regulated degradation by the
proteasome [24,25] and measured the protein half-life (Figure S4).
We found that neither was affected by CCT020312, nor were
there detectable alterations in the cyclin D1 mRNA within the
relevant time period (Figure S4), indicating that CCT020312 does
Figure 1. Chemical structure and properties of screen identified hits. A) Compound chemical structures. Compounds are arranged in
order of decreasing potency. B) Summary of cellular effects and rationale for compound triage. EC50 values for inhibition of pRB
phosphorylation and GI50 values for inhibition of cell growth represent the calculated mean (n=3). The cell-based immunoassay for the detection of
pRB-P-Ser608 (Barrie et al. 2003) was run in HT29 colon carcinoma cells and used to quantify the EC50 for inhibition of pRB phosphorylation at
24 hours, with sulphorhodamine B staining to quantify the GI50 values at 96 hours post compound addition. Protein remaining in wells at 24 hours
was determined using bicinchoninic acid assays.
doi:10.1371/journal.pone.0028568.g001
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e28568Figure 2. Cellular responses to CCT020312 treatment. A) Concentration-dependence of P-S608-pRB loss in CCT020312-exposed
cells. HT29 cells seeded in 96-well plates were exposed to CCT020312 for 24 hours. Ser608 pRB phosphorylation was quantified using the cell-based
immunoassay for the detection of pRB-P-Ser608 as employed for the primary screen (Barrie et al. 2003). Signals normalized to protein content (BCA
assay) are shown. Error bars represent the standard error of the mean (n23). The range for linear response is indicated. B) C) Effects of CCT020312
on cell cycle progression and DNA synthesis. HT29 cells were treated for 16 and 24 hours with 10 mM CCT020312. Cells were stained with
propidium iodide and analysed by flow-cytometry (B). Cells were treated with CCT020312 for 16 or 24 hours. BrdU was added to the medium for the
final two hours. Cells were stained with anti-BrdU antibody and analysed by flow-cytometry (C). D) Accumulation of Ser608 unphosphorylated
pRB in CCT020312 exposed cells. HT29 cells were incubated in the presence of the vehicle (MOCK) or CCT020312 for 24 hours and analysed by
immunoblotting. NP-pRB denotes use of the antibody for detection of the non-phosphorylated Ser608 pRB site. E) Marker expression 24 h post
CCT020312 exposure. HT29 cells were exposed to 10 mM CCT020312 or vehicle (MOCK) for 24 hours. Lysates were analysed by immunoblot for
marker proteins as indicated. Membrane staining with amido black documents loading. F) CCT020312 induces a rapid loss of D cyclin
expression. HT29 cells were treated with 10 mM CCT020312 for the times indicated and lysates analyzed as in E. Tubulin probing documents
loading.
doi:10.1371/journal.pone.0028568.g002
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stability.
cDNA microarray-based transcriptional profiling reveals a
candidate mechanism of action
As an unbiased approach to determine the mechanism by which
CCT020312 elicits its effects, we performed cDNA microarray-
based transcriptional profiling using mRNA from HT29 cells
treated for different times with either 10 mM CCT020312
or vehicle (Dimethyl sulfoxide, DMSO). To interpret the
CCT020312-induced gene expression changes we employed
Connectivity Map (cmap), a tool based on pattern matching for
the discovery of functional connections between pharmacological
agents [26]. This revealed close similarity to the gene regulatory
signature of thioridazine, a neuroleptic dopamine antagonist
without known links to cyclin D expression, and also to 15-delta
prostaglandin J2, which is known to cause a rapid reduction of
cyclin D1 protein through the activation of the eukaryotic
translation factor 2A (EIF2A) Serine 51 (Ser51) kinase EI-
F2AK3/PERK, leading to inhibition of cyclin D1 mRNA
translation [27], see Table S1. We note that there is no structural
resemblance between CCT020312 and either of these agents,
suggesting that their common transcriptional effects are based on
independent chemistry.
We also performed Euclidian distance metric clustering of the
CCT020312 data alongside cDNA microarray data for 22 different
targeted agents previously analyzed in the Cancer Research UK
Cancer Therapeutics Unit using the CRUKDMF_22K_v1.0.0
(GEO accession GPL4348) or the CRUKDMF_WGA_v1.0.0
(GEO accession GPL3904) cDNA microarray platform (Figure 3).
This revealed co-clustering of CCT020312 with the heat shock
protein 90 (HSP90) molecular chaperone inhibitor 17-allylamino-
17-demethoxy-geldanamycin (17-AAG) and the sarco/endoplasmic
reticulum Ca
2+ ATPase targeting agent thapsigargin (Figure 3B)
which, like 15-delta prostaglandinJ2, triggers EIF2A phosphoryla-
tion though EIF2AK3/PERK. A subsequently generated cDNA
microarray data set from cells treated with polyinosinic-polycy-
tidylic acid (poly (I:C)), another effector of EIF2A phosphorylation,
also clustered with CCT020312. An adjacent cluster (cluster II)
contained phosphatidylinositol 3-kinase (PI3K) targeting agents
with differing scaffolds (Figure 3B).
CCT020312 elicits EIF2A phosphorylation in cells
On the basis of the above mRNA profiling analysis we
hypothesised that CCT020312 might act by inhibiting HSP90
Figure 3. Mechanism of action predictions using cDNA microarray-based cluster analysis. A) Cluster analysis. Data from CCT020312
and 22 other molecularly targeted agents, 296 samples in total, established using either the CRUK Human Whole Genome-wide Array v1.0.0 or the
CRUKDMF_22K_v1.0.0 array were used. Genes that significantly varied with treatment (ANOVA p,0.05 with Bonferoni-correction) were used for
hierarchical clustering. Clustering was performed using the Euclidian distance as a similarity measure. B) Cluster deconvolution. Conditions that
cluster with (Cluster I) or adjacent to (Cluster II) CCT020312 are shown.
doi:10.1371/journal.pone.0028568.g003
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probed lysates prepared from HT29 cells treated with
CCT020312 for biomarkers indicative of these respective events.
We found no evidence of reduced phosphorylation of the PI3K
target AKT/PKB (Ser473) nor of ribosomal protein S6 kinase
RPS6KB1 (Thr299), [28] (not shown), nor induction of heat shock
protein 70, known to ensue from HSP90 inhibition [29] (not
shown). In contrast a clear increase in phosphorylation of EIF2A
on Ser51 was seen upon treatment of either HT29 or MCF7 cells
with CCT020312 (Figure 4A, see Figure S5 for quantification).
Rapid loss of D cyclins is a known event linked to attenuation of
protein translation following EIF2A phosphorylation [30,31] and
hence readily explained by this mode of signalling. Together these
results strongly support a mechanism in which CCT020312 acts as
an effector of Ser51 EIF2A phosphorylation.
To determine the structural requirements for activity and
biomarker modulation seen in CCT020312-treated cells we studied
several analogues (Figure 4C). These studies revealed a tight
correlation between growth inhibition, retinoblastoma protein
activation and the activation of EIF2A phosphorylation
(Figure 4B). Removal of lipophilicity from the core scaffold of
CT020312 (exemplified by analogues CRT53900 and CRT54039)
Figure 4. EIF2A phosphorylation in CCT020312-treated cells. A) Detection of EIF2A phosphorylation following CCT020312
treatment. HT29 human colon cancer and MCF-7 human breast cancer cells were treated with 10 mM CCT020312 (+) or vehicle () for the times
indicated. Lysates were prepared and immunoblot-analysis performed using antibodies to detect EIF2A and Ser51-phosphorylated EIF2A (P-
S51EIF2A) as indicated. B) Structure-activity relationships. Representatives from different chemical series were tested using HT29 cells for their
respective ability to activate EIF2A phosphorylation. C) Analogue structures and potency of analogues for reducing P-S608-pRB and
growth.
doi:10.1371/journal.pone.0028568.g004
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both RB phosphorylation and cell growth assays. Likewise these
analogues lost the capacity to activate EIF2A phosphorylation.
Analogues CRT54048 and CRT54045, in which lipophilicity was
restored by the introduction of a biphenyl ring system, regained
activity. Significantly these compounds also regained the ability to
trigger EIF2A phosphorylation although a two-fold higher concen-
tration was required to achieve a level of response comparable to
CCT020312, consistent with the slightly reduced potency of these
analogues in other assays. Analogues CT129131 and CT129132
prepared through successive removal of the two N-ethyl groups
retained the ability to activate pRB and inhibit growth with only
slight (two- to three-fold) reduction in potency; the ability to trigger
EIF2A phosphorylation was retained although a two-fold higher
concentration was again required. Hence a close structure-activity
relationship exists between the inhibition of pRB phosphorylation,
growth inhibition and the activation of EIF2A phosphorylation,
supporting the view that these activities are mechanistically linked.
EIF2A phosphorylation and cyclin D1 loss by CCT020312
requires EIF2AK3/PERK
EIF2A phosphorylation arises from activation of four different
EIF2A kinases (EIF2AK1-4) that respond to distinct signalling cues
Figure 5. Signalling leading to CCT020312-dependent EIF2A phophorylation. A) Schematic showing EIF2A kinases and their
regulation. Pathway agonists thapsigargin, poly (I:C) and NaAS2O3 and their locus of action are indicated. B) Effect of EIF2AK3/PERK ablation
on EIF2A phosphorylation by CCT020312. U-2OS human osteosarcoma cells were transfected with either of two different EIF2AK3/PERK siRNA
oligonucleotides (PERK-1, PERK-2) or an irrelevant control (NT) for 72 hours. Cells were treated with 10 mM CCT020312 (CCT) or 2 mM thapsigargin (Tg)
for the indicated times. Lysates were analysed by immunoblot as indicated. C) Quantitation of PERK mRNA expression in siPERK transfected
cells. PERK mRNA was quantified in siRNA tranfected cells using SYBR Green based quantitative PCR. The comparative cycle threshold method was
used to determine the fold change in PERK mRNA relative to cells tranfected with irrelevant oligonucleotide. GAPDH was quantified in parallel and
used to normalise between samples. Bars represent the mean fold change in triplicate technical replicates. D) Ablation of EIF2AK3/PERK
prevents CCT020312-mediated cyclin D loss and accumulation of underphosphorylated pRB. HCT116 human colon cancer cells were
transfected with EIF2AK3/PERK siRNA oligo ‘2’ or non-targeting siRNA (NT). After 72 hours cells were treated with 10 mM CCT020312, 2 mM
thapsigargin (Tg) or DMSO for times indicated. Cell lysates were analysed by immunoblotting as indicated.
doi:10.1371/journal.pone.0028568.g005
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accumulating in erythrocytes or oxidative stress, EIF2AK2/PKR
by double-stranded RNA, EIF2AK3/PERK through an increase
of unfolded proteins in the endoplasmic reticulum and EIF2AK4/
GCN2 through deprivation of essential amino acids.
We tested for the involvement of these different EIF2AKs in the
response to CCT020312. EIF2AK3/PERK depletion using small
interfering RNA (siRNA) oligonucleotides strongly attenuated
Ser51 EIF2A phosphorylation induced in response to CCT020312
or thapsigargin (Figure 5B, results quantified in Figure S6), and
this was seen with two unrelated PERK targeting oligonucleotides.
qPCR- based mRNA quantification (Figure 5C) revealed reduc-
tion of EIF2AK3/PERK mRNA in cells transfected with either
oligonucleotide. Efficacy of depletion was higher in PERK-2 than
PERK-1-transfected cells, consistent with the superior reduction of
signalling seen in cells transfected with PERK-2 olignucleotide
(Figure 5B). Knockdown of EIF2AK3/PERK also abolished cyclin
D1 loss and the accumulation of underphosphorylated pRB arising
subsequent to treatment with both agents, consistent with our
hypothesis that these molecular events result from the activation of
EIF2AK3/PERK signalling by CCT020312 or thapsigargin
(Figure 5D, results quantified in Figure S6). Ablation of
EIF2AK2/PKR by siRNA had no effect, although its knockdown
inhibited EIF2A phosphorylation in response to poly (I:C), a
known activator of this EIF2AK (Figure S7). Likewise, addition of
hemin, which inhibits EIF2AK1/HRI [34] and which suppressed
EIF2A phosphorylation in cells exposed to oxidative stress, did not
affect EIF2A phosphorylation in cells treated with CCT020312
(Figure S7). Together these observations clearly indicate the
critical involvement of EIF2AK3/PERK in the phosphorylation of
EIF2A, cyclin D loss and the attenuation of pRB phosphorylation
seen in CCT020312-treated cancer cells.
Selective stimulation of EIF2A signalling by CCT020312
EIF2AK3/PERK activation and the consequent phosphoryla-
tion of EIF2A classically ensue as part of the unfolded protein
response (UPR) [35]. The UPR is initiated when unfolded or
misfolded proteins accumulate in the lumen of the endoplasmic
reticulum, leading to EIF2AK3/PERK activation and, as a
consequence, activating transcription factor 4 (ATF4) driven gene
transcription, but also other signalling, unrelated to EIF2AK3/
PERK (see Figure 6A). Thus, transcription factor ATF6 is released
from its ER membrane position allowing translocation to the cell
nucleus. Furthermore, protein kinase and nuclease inositol-
requiring 1 (IRE1) is activated and facilitates mRNA processing
to produce the spliced variant form of the X-box transcription
factor XBP1 (XBP1s) [35].
To assess whether ATF6 and IRE1 are activated alongside
EIF2AK3/PERK, CCT020312-treated HT29 colon cancer and
MCF7 breast cancer cells were probed for markers downstream of
these different signalling effectors. Consistent with its effect on
Ser51-EIF2A phosphorylation, CCT020312-treatment of both cell
types resulted in accumulation of the ATF4 target C/EBP
homology protein/growth arrest and DNA damage 153
(CHOP/Gadd153) (Figure 6B). However, induction of the ATF6
target 78 kDa glucose-regulated protein/Binding immunoglobulin
protein (GRP78/BIP) was virtually undetectable, even at late
times (16 h, Figure 6B) or following treatment with higher
concentrations of CCT020312 (Figure 6C). Induction of
GRP78/BIP was readily detected in parallel cultures of these
cells treated with thapsigargin. We also isolated mRNA from
CCT020312 and thapsigargin-treated HCT116 and HT29 cells
and probed for the presence of spliced XBP1 transcript using PCR
(Figure S8). Spliced XBP1 mRNA was not detected in
CCT020312-treated cells but was readily detected in thapsigar-
gin-treated cells (Figure S8). As observed previously, EIF2A
phosphorylation was readily increased following both treatments
in parallel samples (Figure S8), indicative that CCT020312 as well
as thapsigargin had both elicited EIF2AK activation. These results
suggest that, in contrast to thapsigargin, CCT020312 does not act
by triggering the full spectrum of UPR responses.
Inspection of mRNA expression patterns based on the cDNA
microarray analysis described earlier supports this hypothesis
(Figure S9). Expression of two genes, GRP94/HSP90B1 and
DNAJ3/p58IPK, recently shown to be regulated during UPR
through the IRE1 effector XBP1 [36] was not up-regulated in
CCT020312-treated cells, although these genes were up-regulated
in thapsigargin-treated cells (Figure S9). However, up-regulation of
mRNA for CHOP/Gadd135 and the tryptophanyl-tRNA synthe-
tase WARS, previously shown to depend on EIF2A phosphory-
lation [37], was seen with both treatments (Figure S9).
Confirmatory evidence for the absence of outright UPR also
came from the analysis of primary mouse embryonic fibroblasts
(MEFs), a cell model that has been used for establishing many of
the concepts of UPR signalling transmission in mammals [35].
CCT020312 treatment of the MEFs led to CHOP induction,
whilst accumulation of the small splice-variant of XBP1 (XBP1s)
was not triggered. Rapid XBP1s accumulation was however seen
when these cells were treated with thapsigargin (Figure S9).
CCT020312 also suppressed cyclin D1 expression in these
fibroblasts. These observations are consistent with the involvement
of EIF2AK3/PERK activity in the CCT020312 elicited effects but
strongly argue against induction of full UPR as the molecular
mechanism by which CCT020312 acts.
To probe for the significance of PERK in the antiproliferative
action of CCT020312, we used SV40 immortalised fibroblasts
from wild-type (wt) and PERK knockout (PERK 2/2) mouse
embryos ([38]) (Figure 7). In keeping with our earlier results
indicating EIF2AK3/PERK-dependence of the CCT020312-
induced EIF2A phosphorylation we found EIF2A phosphorylation
to be radically reduced in PERK 2/2 MEFs following exposure
to either thapsigargin or CCT020312 (Figure 7A,B). Significantly,
cell cycle analysis revealed a considerable distortion of the cell
cycle profile in wt MEFs following CCT020312 treatment, with
overt inhibition of progression into G2/M-phase, as revealed
when a nocodazole-induced G2/M block was established
following exposure of these wt MEFs to CCT020312 (Figure 7C,
D). We note that these cells did not respond with G1-phase
accumulation (2n) to CCT020312, consistent with the notion that
this arrest is facilitated by pRB and its orthologues which in these
MEFs are inactivated as a consequence of SV40 transformation.
Instead they respond with increased S-phase accumulation (223n)
and apoptosis, as revealed by the increase of cells with a sub G1
DNA content (,2n). Neither of these responses were evident in
paired SV40-transformed PERK2/2 MEFs (Figure 7C, D).
Instead these PERK-modified cells were capable of moving into
G2 with identical efficacy, irrespective of whether CCT020312
was present or absent, indicative that cell cycle transit in these cells
is not affected by CCT020312. These results fully support the
notion that selective activation of EIF2AK3/PERK signalling is
the mode of action through which CCT020312 causes attenuation
of cell cycle transit and inhibition of proliferation.
Interaction of CCT020312 with paclitaxel
Recent work indicates a link between ER stress-mediated
EIF2AK3/PERK signalling and the cellular sensitivity to multiple
anticancer agents, including taxanes [39,40]. We therefore evaluated
if CCT020312 could enhance the sensitivity of cells to paclitaxel. We
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EIF2A phosphorylation inresponse to paclitaxel, and HCT116 colon
cancer cells, in which EIF2A phosphorylation increases upon
treatment with this drug (Figure 8A), with increasing concentrations
of paclitaxel, either alone or in combination with CCT020312.
Exposure of both these celltypes to 2.5 mM CCT020312 resulted in a
c l e a ra u g m e n t a t i o no ft h ep a c l i t a x e l - i n d u c e dg r o w t hi n h i b i t i o ni nU -
2OS cells but had no effect in HCT116 cells (Figure 8B). Fixed ratios
of paclitaxel and CCT020312 across a 25-fold range yielded
combination indices that were consistently less than one (,1) in U-
2OS, indicating a greater than additive interaction of these two
agents using median effect analysis [41]. In contrast, combination
indices of greater than one (.1) were obtained in HCT116 cells,
indicating a less than additive interaction between CCT020312 and
paclitaxel in these cells (Figure 8C and Figure S10). Experiments in
cells with taxane resistance due to increased multidrug resistance
(MDR1) P-glycoprotein expression did not reveal synergy between
CCT020312 and paclitaxel, nor did the ablation of p53, thought to
mediate apoptosis in HCT116 cells, cause cooperation (not shown).
This suggests that a selective complementation of EIF2AK3/PERK
signalling deficiency underlies the cooperation between CCT020312
and paclitaxel seen in U2-OS osteosarcoma cells. Thus in addition to
its ability to confer G1/S checkpoint activation and proliferation
control, CCT020312, or agents like it, may hold promise in
conferring sensitization of cancer cells in specific situations of
paclitaxel resistance.
Figure 6. CCT020312 does not induce full ER stress signalling. A) Schematic of unfolded protein response signalling. Response
biomarkers are indicated. B) UPR response marker expression in HT29 colon and MCF7 breast cancer cells. Cells were treated with
CCT020312 (CCT, 10 mM) or thapsigargin (Tg, 2 mM) as indicated and analysed by immunoblotting for CHOP/GADD153 and GRP78/BIP. C) UPR
response marker expression following CCT020312 dose escalation. HT29 cells were treated for 16 h. Lysates were analyzed as in B.
doi:10.1371/journal.pone.0028568.g006
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We previously described a mechanism-based screening ap-
proach to isolate G1/S checkpoint activating agents [20]. Using
this approach we have identified several structurally unrelated
chemical series, including CCT020312, and report here the
mechanism of action by which this agent achieves checkpoint
activation in cells. Our analysis indicates that CCT020312
promotes EIF2A phosphorylation with the known consequence
of D-type cyclin depletion and a loss of ability to phosphorylate
pRB. Our results identify loss of cyclin D expression as a major
and early event in CCT020312-treated cells and show this, along
Figure 7. Effects of CCT020312 exposure on wild type and PERK KO MEFs. A) EIF2A phosphorylation. SV40-immortalised wild type (WT)
and PERK KO MEFs (PERK2/2) were treated with 10 mM CCT020312 (CCT), 2 mM thapsigargin (Tg) for the time indicated. Cell lysates were analysed
using P-S51 EIF2A and pan EIF2A selective antibody. The position of P-S51 EIF2A is indicated with an arrow beneath an unrelated, high molecular
weight, non-specific band (*). B) Signal quantification for data shown in A). Charts depict the background corrected signal for P-S51 EIF2A
relative to that of pan EIF2A in the same samples. Signals were quantified using Image J. C) Cell cycle response. MEFs were treated with 10 mM
CCT020312 or vehicle (DMSO) for 30 hrs and analysed for cell cycle distribution. Where indicated, Nocodazole (Noc) was added to the culture
medium at a concentration of 1 mg/ml for the final 16 hours. Raw propidium iodide profiles are shown. Cells were treated in parallel to those
analysed for A. D) Quantitative analysis of cell cycle distribution. Experiments were as described for C). Charts depict the percentage of cells
with DNA content as indicated, nocodazole was added where indicated. Results for two independently run experiments are shown.
doi:10.1371/journal.pone.0028568.g007
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consequence of EIF2AK3/PERK signalling. Together these
results identify EIF2AK3/PERK signalling as the target mecha-
nism through which CCT020312 achieves G1/S checkpoint
activation, corroborating earlier evidence that link this signalling
pathway to the control of CDK4/6 activation in mammalian cells
[30].
EIF2AK3/PERK activation forms part of the UPR that arrests
cell proliferation following accumulation of unfolded proteins in
the ER. However UPR signalling involves other events in addition
to EIF2AK3/PERK activation, including membrane release and
activation of ATF6 and IRE1 [42] leading to activation of a
complex transcriptional response both independent of, and
collaborative with, EIF2AK3/PERK activation. Our analysis
indicates that CCT020312 does not induce responeses that ensue
from activation of IRE1 or ATF6, although it effectively stimulates
EIF2A phosphorylation and associated downstream signalling
linked to this event. Hence, our results show that CCT020312
does not elicit UPR, but that it acts selectively to instigate
proliferation inhibition through an EIF2A phosphorylation-
associated translation inhibition. While EIF2AK3/PERK activa-
tion is consistently seen with agents that disable ER function, these
agents classically trigger full UPR. To our knowledge agents with
selectivity for eliciting EIF2AK3/PERK signalling alone have not
been described previously.
While the precise way through which CCT020312 elicits
EIF2AK3/PERK signalling has not yet been elucidated, the
current knowledge as to how activation of this kinase is achieved
implies a narrow set of options. EIF2AK3/PERK auto-activates
through oligomerization-induced autophosphorylation [43,44].
Figure 8. Interaction of CCT020312 with paclitaxel. A) Paclitaxel-associated EIF2A phosphorylation in U-2OS and HCT116 cells. U-
2OS and HCT116 were exposed to 10 mM CCT020312 (CCT), DMSO or paclitaxel (taxol) for 4 hours. Cell lysates were analyzed by immunoblotting for
P-S51-EIF2A and tubulin. B) Proliferation inhibition by paclitaxel in the presence of CCT020312. Cells were treated with increasing amounts
(1–25 nM) of paclitaxel in the absence and presence of a fixed dose (2.5 mM) of CCT020312. Arrows denote proliferation inhibition in cells treated
with 2.5 mM CCT020312 only. Cell lines were as indicated. C) Multiple drugs effect analysis: U-2OS and HCT116 cells were treated with escalating
doses of paclitaxel, CCT020312 or their combination. Combination indices (CIs) for each dose are shown. The calculated mean CI and standard error is
indicated. ‘‘CI excl’’ assumes agents act by a competing, mutually exclusive mechanism of action, ‘‘CI no-exl. assumes agents act through distinct,
exclusive mechanisms of action [57].
doi:10.1371/journal.pone.0028568.g008
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from competition between unfolded ER protein clients and
EIF2AK3/PERK for the chaperone heat shock 70 kDa protein
5 (HSPA5)/GRP78/BIP, which associates with and prevents
oligomerization of the kinase. However, HSPA5/GRP78/BIP also
controls ATF6 and IRE1 [45], which according to our analysis are
not activated by CCT020312. Hence outright interference with
HSPA5/GRP78/BIP functioning cannot explain the mechanism
of action of CCT020312. More conceivable is a mode of action
whereby CCT020312 interacts with EIF2AK3/PERK, either
preventing the association of this kinase with HSPA5/GRP78/BIP
or promoting HSPA5/GRP78/BIP-resistant oligomerization. It is
also possible that CCT020312 prevents feedback regulation that
silences EIF2AK3/PERK signalling following activation by
spurious ER stress as part of normal cell homeostasis. Feedback
regulation during UPR involves enhanced production of protein
phosphatase 1 regulatory subunit 15A (PPP1R15A)/GADD34
consequent to ATF4 activation (see Figure 6A), which in turn
recruits the serine/threonine-protein phosphatase PP1 to dephos-
phorylate EIF2A [46]. A previous chemical biology approach
identified salubrinol as an inhibitor of PP1-mediated EIF2A
dephosphorylation. Like CCT020312, salubrinol provokes upre-
gulation of CHOP/GADD153, but does not initiate XBP1
splicing or GRP78/BIP production [47]. However, and in contrast
to CCT020312, salubrinol induces Ser51 phosphorylation of
EIF2A in EIF2AK3/PERK-negative backgrounds, indicating that
the mechanism of action of salubrinol and that of CCT020312 are
mechanistically distinct.
We demonstrate potent antiproliferative activity of CCT020312
at low mmolar concentrations, which is detectable in both p53
positive (HCT116) and p53 negative (HT29) human colon cancer
cells and remains considerable even under conditions of time-
limited exposure to the compound. The known consequences of
EIF2AK3/PERK activation are consistent with these observations.
While the initial result of EIF2AK3 activation is acute inhibition of
protein translation, leading to G1 restriction point activation and
arrest, prolonged activation is linked to loss of cell viability,
conceivably due to an inability to produce anti-apoptotic proteins,
which many cancer cells rely upon [48,49]. The well-recognized
dependence of cancer cells on anti-apoptotic functions may
constitute a cancer-selective therapeutic window for the treatment
with agents such as CCT020312. Recent work has implied the
involvement of ER stress signalling in mediating the potency of
several unrelated cytotoxic agents including, paclitaxel fluorouracil
and cisplatin [39], as well as a supporting role of EIF2A
phosphorylation in the response to anticancer agents targeting the
ubiquitin/proteasome pathway [50,51], indicating added utility for
agents such as CCT020312 that are able to activate this form of
signalling. In agreement with this hypothesis, we have demonstrated
the ability of CCT020312 to sensitize cells that lack paclitaxel-
mediatedEIF2Aphosphorylationresponsetothecytotoxiceffectsof
paclitaxel. Apart from its intrinsic antiproliferative mode of action,
CCT020312 and agents like it may be suitable for use in
combinationwith paclitaxeland potentially other anticancer agents.
Furthermore, EIF2AK3/PERK signalling has been found to
alleviate beta-amyloid associated neurotoxicity [52] and reduce
brainstem motor neurone death in a murine model of sleep apnea
[53], suggesting that EIF2AK3/PERK pathway activation could be
a potential target for therapeutic fields other than cancer, including
conditions of hypoxia-associated neurotoxicity and neurodegener-
ative disorders such as Alzheimers disease. CCT020312 could serve
as a mechanistic tool for proof-of-concept explorative experimen-
tation in these various contexts and may provide a candidate for
chemical optimization.
Materials and Methods
Cell culture and agent treatment
Cell lines were obtained from ATCC and maintained in
DMEM or RPMI (GibcoBRl) containing 10% FCS. Primary
MEFs were isolated from day 13.5 embryos. T antigen
immortalised PERK +/+ and 2/2 MEFs were kindly provided
by the Ron laboratory. MEFs were maintained in DMEM
Supplemented with 10% FCS, 5 mM glutamine, antibiotics, 16
MEM non-essential amino acids and 55 mM 2-mercaptoethanol.
Unless stated otherwise cells were seeded at subconfluent density
and cultured for 24 h prior to agent treatment. CCT020312 was
dissolved in DMSO at a concentration of 10 mM and stored at
270uC. Thapsigargin (Sigma) was dissolved in DMSO at a
concentration of 2 mM and used at the indicated concentrations
to induce EIF2AK2/PERK-mediated EIF2A phosphorylation.
Poly (I:C) and sodium arsenite (NaAS2O3, Sigma, aqueous
solution) were employed at the indicated concentrations to induce
EIF2A phosphorylation by EIF2AK2/PKR and EIF2AK1/HRI,
respectively. Hemin chloride (Sigma) was dissolved in DMSO and
used at the indicated concentrations to block EIF2AK1/HRI
activity in cells. All agents were made up in growth medium, 10%
FCS at their respective working concentrations immediately prior
to addition to the adherent cells. To monitor cyclin D1 protein
stability cells were treated with 20 mg/ml cycloheximide in the
absence or presence of CCT020312.
Compounds and Compound screening
The Cell-based immunoassay for the detection of pRB-P-
Ser608 has been described [20]. The assay used a mouse
monoclonal antibody that recognizes the phosphorylated form of
Ser 608 on pRb on a fixed monolayer of cells seeded in a 96 well
format in combination with a Europium-labelled secondary
antibody for signal detection. Signal detection was by a time-
resolved fluorescence. The Cancer Therapeutics Unit internal
compound collection (.63.000 compounds), comprising a selec-
tion of diverse small molecules either purchased from commercial
suppliers, archived in-house or obtained through Cancer Research
UK was screened in a 96 well format using conditions essentially
as described in [20]. Compounds were used at 10 mM with assay
endpoint at 24 h following compound addition. To identify
candidate hits, data were filtered for reduction of signal by 50%
or greater compared to the means of quadruple DMSO controls
run in parallel in the same plate. Values were normalized to
protein retained in the wells at the assay endpoint. All plates
passed the quality control criteria of Z factor .0.4 [54]. Hits were
confirmed using the screening assay and positives further validated
by immunoblot using pan pRB antibody (14001A, Pharmingen)
and antibody selective for Ser608 unphosphoryated pRB (14441A,
Pharmingen). Preparation of CCT020312 and generation of
analogues is described below. Structural integrity and purity of
compounds including the original hit matter was established and
confirmed using mass spectrometry.
Cell lysate preparation, immunoblot analysis and
antibodies
Cell lysates for immunoblot analysis were prepared in 50 mM
Hepes-KOH pH 7.4, 250 mM NaCl, 5 mM EDTA, 0.5% Triton,
10 mM-glycerophosphate, 10 mM NaF, 1 mM NaVO3, 1 mM
DTT, 1 mM PMSF, 1% aprotinin, 2.5 mg/ml leupeptin). Lysates
were cleared by centrifugation at 10,0006 g for 10 minutes at
4uC. Protein content was estimated by Bradford assay (Bio-Rad).
Immunoblots were performed using standard procedures. Protein
antibody complex was detected using horseradish peroxidase
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minescence ECL according to the manufacturer’s instructions (GE
healthcare). Primary antibodies used were; anti pRB-phospho-
Ser608 antibody (P-S608-pRB, Barrie et al. 2003) pan pRB
(14001A, Pharmingen), non-phospho-Ser608 pRB (NP-pRB,
14441A, Pharmingen), Cyclin D1 (554181, Pharmingen), anti
pRB Phopsho-Ser780 (P-S780-pRB, a gift from Onyx Pharma-
ceuticals), anti-pRB-phospho-Ser807/811 (P-S807/811-pRB, Sig-
ma), Cyclin D3 (C-16, Santa Cruz), Cyclin E (14591c, Pharmin-
gen), Cyclin A (BF683, Santa Cruz), CDK4 (H-22, Santa Cruz),
CDK6 (C-21 Santa Cruz), CDK2 (M2, Santa Cruz), p27
KIP1
(C19, Santa Cruz), phospho-Ser473 AKT (Cell Signalling), AKT
(Cell Signalling), anti EIF2A (Cell Signaling), phospho-Ser51
EIF2A (P-S51-EIF2A, Cell Signalling), HSP70 (W27, Neomar-
kers), GADD153/CHOP (F-168, Santa Cruz), GRP78/BIP (H-
129, Santa Cruz), EIF2AK2/PKR (Cell Signalling) and b-tubulin
(Neomarkers).
siRNA-mediated gene silencing
Cells were transfected with siRNA oligonucleotide at 20 nM
using the HiPerFect lipid reagent (Qiagen) as per the manufac-
turer’s published guidelines for the transfection of adherent cell
lines. Oligonucleotides used for EIF2AK3/PERK knockdown
were 59-uaa acc guu aua cag uuu gtg-39 (EIF2AK3-1) and 59-uua
acu ucu cgc auu acc utt-39 (EIF2AK3-2). For EIF2AK2/PKR the
Dharmacon Smartpool (M-003527-00) was used.
Generation of recombinant cyclin/CDK enzymes and
phosphorylation activity assay
Kinases were produced in Spodoptera frugiperda (SF9) insect
cells. Cells were infected with pairs of cyclin and CDK-encoding
baculoviruses, and kinases produced as recently described [55].
Purified baculovirus-produced Cyclin B/CDK1 was purchased
from Upstate Biotechnology.Purified baculorvirus-producedCyclin
D1/CDK4 was a gift from Onyx Pharmaceuticals. Test tube
reactions were assembled containing 50 mM HEPES-KOH,
pH 7.4, 10 mM MgCl2, 10 mM MnCl2, 1 mM EDTA, 10 mM
B-glycerophosphate, 0.1 mM protein kinase A inhibitor, 1 mM
DTT, 1 mM PMSF, 1% aprotinin, 2.5 mg/ml leupeptin, with
10 mM ATP and 0.5 mCi [gamma 232P] ATP and 10 mg/ml
Gluthathione-S-transferase (GST) fused pRB fragment, aa 792–928
(GST-pRB-ct) as the substrate. Compounds were added to the
reaction prior to enzyme addition. Final reaction volumes were
50 ml and the reaction time 15 min at 30uC. Reactions were
stopped using SDS containing sample buffer and analyzed using
denaturing polyacrylamide gel electrophoresis with subsequent
autoradiography. For plate-based kinase activity assays Immulon
R
plates (Thermo Scientific) were coated with 1 mg per well of GST-
pRB-ct in PBS. Plates were washed 3 times in PBS, 0.1% Tween 20
prior to use. Reactions were assembled containing 50 mM HEPES
pH 7.4, 10 mM NaF, 1 mM sodium orthovanadate, 1 mM DTT,
10% glycerol, 25 mM ATP, 10 mM MgCl2 and enzyme. Com-
pounds were added prior to addition of enzyme. Reactions were
carried out for a set time at 30uC and stopped by adding 50 ml cold
0.2 M EDTA. Substrate phosphorylation was quantified using
phosphorylation-selective anti-pRB antibody detection involving
europium labelled secondary antibody (Perkin Elmer). Phopsho-
Ser780pRBwasusedforquantificationofCDK4activity,phospho-
Ser807/811 pRB for the quantification of CDK1 activity.
Cell cycle analysis and proliferation assays
Cell cycle analysis was performed using standard procedures
and as described [56]. Propidium Iodide (PI) staining was used to
determine the DNA content and Bromodeoxyuridine (BrdU) pulse
labelling to assess DNA synthesis activity. The proliferation
activity of cells was quantified using a standard sulphorhodamine
B (SRB) colorimetric assay in a 96-well assay format. GI50 values
were calculated by non-linear regression using the Prism V4.0
software. Multiple drug effect analysis was performed as described
[41]. Combination index (CI) values were derived from param-
eters of the median effects plots. Statistical tests (unpaired, two-tail
Student t test) were used to determine whether the mean CI values
at multiple concentrations were significantly different from CI=1.
RNA preparation and transcript analysis
RNA for microarray analysis was generated by growing
0.7610
6 HT29 cells in 20 cm tissue culture dishes. After 48 h
growth cells were exposed to either 7 mM CCT020312, 220 mg/
ml Poly (I:C) or 2 mM thapsigargin for various times. Floating and
adherent cells for each time point were pooled and processed.
Total RNA was isolated using RNACell (Applied Biossytems) on
the ABI 6100 nucleic acid prepstation, following the manufactur-
er’s instructions. The CyScribe Post-Labeling Kit (GE Healthcare)
was used to label 5 mg of total RNA according to the
manufacturer’s recommendations. Reference samples were la-
belled with cy5 and the drug-treated test samples with cy3.
Labelled test and reference samples were mixed and hybridised to
the CRUK Human Whole Genome-wide Array v1.0.0 printed on
type 7* slides (GE Healthcare). Arrays were hybridised for 3 days
at 42uC.
The cy3 and cy5 signals were detected and visualized using a
GenePix 4000B scanner and software (Axon Instruments, Foster
City, CA, USA). Spots were curated and filtered for quality by
automated spot flagging. Spots were assigned a good flag if the
signal intensity was 1 standard deviation above background in
75% of the pixels in either channel, with a signal saturation of less
then 3% in either channel. The output of the automated flagging
was inspected visually and adjusted when necessary. The GenePix
raw data files were analysed in Genespring (Agilent Technologies)
using the ‘‘per–spot’’ and ‘‘per-chip’’ intensity–dependent Lowess
normalization. A Lowess curve was fit through the log-intensity
versus log-ratio plot. 20% of the data was used to calculate the
Lowess fit at each point. This curve was used to adjust the control
value for each measurement. Only genes that fulfilled the good flag
criteria in at least 67% of the samples were used for analysis.
Replicate samples were averaged. Genes were considered changed
when a 1.5 fold change was observed relative to untreated controls
for 2 or more time points. Genes that were modified by DMSO
treatment were removed from the analysis. Hierarchical clustering
was performed using Euclidian distance as the metric.
RNA for quantitative PCR analysis was prepared from cells in
6-well plates using RNeasy (Qiagen) assuming 1610
6 cells/well
and using the manufacturer’s ‘Animal Cells Spin’ protocol and
QIAshredder option. Quantitative PCR was performed by a 2-
step protocol involving a round of first strand cDNA synthesis and
PCR amplification in the presence of SYBR green (Qiagen).
Ready-To-Go T-Primed First-Strand reactions (GE Healthcare)
were used for first-stand synthesis. The Quantitect SYBR Green
PCR kit and Quantitect validated primer pairs for EIF2AK3/
PERK and GAPDH and Cyclin D1 (Qiagen) were employed to
quantify these transcripts in first-strand samples using an ABI
Prism 7700.
Northern blots were performed using standard formaldhyde
agarose gel electrophoresis. Probes for hybridization were
prepared by PCR and labelled using the BioPrime DNA Labelling
System (Invitrogen). Hybridizatrion and detection followed the
manufactorer’s instructions.
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The synthetic route for CCT020312 and analogues is provided
in Supplemental Methods and Materials S1.
Supporting Information
Figure S1 Effect of CCT020312 on cyclin/CDK activity
in vitro. A), B) ELISA-based activity assay. Enzyme activity
was determined using 96 well microtitre plates coated with 1 mg
per well of GST-pRB-ct. Reactions contained CCT020312 or the
pan CDK inhibitor flavopiridol [6], as indicated. CDK4 activity
was detected using rabbit anti-pRB-P-Ser780 (1:3000), CDK1
activity was detected using rabbit anti-pRB-P-Ser807/811 (Sigma
1:5000) followed by europium-labelled anti-rabbit 2u antibody
(Perkin Elmer, Life Sciences, 0.1 mg/ml). Signals were detected by
time-resolved fluorescence. Curve fit for representative assay (A).
Calculated IC50 average, n=3 (B). C) In vitro phosphorylation
assays. Baculovirus-infected SF9 lysates directing the expression of
CyclinD1/CDK4, Cyclin E/CDK2 or Cyclin A/CDK2 com-
plexes were added to a kinase reaction containing 0.5 mg GST-
pRB-ct as substrate and 10 mM ATP. CCT020312 was added at
the concentrations indicated. K4 and K2 indicate reactions run in
the presence of catalytic subunits CDK4 or CDK2 only. The
CDK1/2 selective inhibitor R-roscovitine was included as a
positive control. Reactions were analysed by SDS gel electropho-
resis followed by autoradiography. Reference. 6. Senderowicz
AM (1999) Flavopiridol: the first cyclin-dependent kinase inhibitor
in human clinical trials. Invest New Drugs 17: 313–320.
(TIF)
Figure S2 Concentration-response relationship for in-
hibition of pRB phosphorylation and proliferation. A)
Concentration-response curve for reduction of pRB
phosphorylation in HT29 and HCT116 colorectal carci-
noma cells. pRB phosphorylation was quantified using im-
munoadsorbance as employed for the primary screen. Signals
normalized to protein content in respective wells are shown. Error
bars represent the standard deviation based on three replicate
experiments. B) Concentration-response curve for growth
inhibition in HT29 and HCT116 colorectal carcinoma
cells. Proliferation was quantified 96 hours post compound
addition using a sulphorhodamine B based colorimetric assay.
C) Growth inhibition following pulse-treatment of cells.
Cells were treated for the time indicated after which compound
containing medium was removed. Proliferation was quantified
96 hours post treatment using a sulphorhodamine B based
colorimetric assay. GI50 calculations were performed by non-
linear regression using the Prism V4.0 software.
(TIF)
Figure S3 Effects of CCT020312 on expression of G1/S
CDKs and their regulators. A) Changes in biomarker
expression over 24 h. HT29 cells were treated with 10 mM
CCT020312 for the periods indicated. Lysates were prepared at
each time point and analysed as in FIG. 2E. B) Loss of cyclin
D1 is widely detected in cell lines treated with
CCT020312. Cell lines as indicated were treated with 10 mM
CCT020312 (+) or vehicle (2) for 6 h. Lysates were analyzed for
cyclin D1 expression by immunoblot. Membrane staining with
amido black (A, D) or probing for tubulin (B, C) was used to reveal
loading.
(TIF)
Figure S4 Effect of CCT020312 on cyclin D1 turnover
and mRNA accumulation. A) CCT020312 does not affect
Cyclin D1 stability. MCF-7 were treated with 20 mg/ml
cycloheximide in combination with 10 mM CCT020312, as
indicated. Lysates were analysed by Immunoblotting using anti
Cyclin D1 and tubulin. A9) quantification of Cyclin D decay using
cy-5 conjugated secondary antibody. Signals were quantified by
PhosphoImager. B) CCT020312 does not trigger Thr286
phosphorylation of Cyclin D1. MCF-7 cells were treated with
10 mM CCT020312 (+) for the times indicated. Lysates were
adjusted for protein content and analysed undiluted or diluted 1:2
by immunoblotting blotting using antibodies as indicated. MCF-7
cells were treated with 100 mM etoposide a known inducer of
cyclin D-Thr286 phosphorylation (B). C), D) Effect of
CCT020312 on cyclin D1 steady mRNA state levels.
MCF-7 cells were treated with 10 mM CCT020312 for the time
indicated. RNA was analysed by SYBR green assisted q PCR (C),
or Northern blot (D). Error bars in C represent the means of four
parallel technical replicates. qPCR reactions were evaluated using
the standard curve method. GAPDH was used as a reference for
normalization.
(TIF)
Figure S5 EIF2A phosphorylation following CCT020312
treatment. Signal quantification for results shown in Figure 4A.
Electronic scans were produced from primary autoradiograms and
analysed using ImageJ (http://rsbweb.nih.gov/ij/). Charts depict
background corrected signal quantities for P-S51 EIF2A relative to
the signal quantities for pan EIF2A in the same samples.
(TIF)
Figure S6 Effect of EIF2AK3/PERK ablation on
CCT020312-mediated EIF2A phosphorylation and loss
of cyclin D and pRB phosphorylation. A) Signal quanti-
fication for results shown in Figure 5B. Charts depict
background corrected signal for P-S51 EIF2A relative to that of
pan EIF2A in the same samples. B) Signal quantification for
results shown in Figure 5C. Charts depict background
corrected raw signal quantities for Cyc D1, nonphosphorylated
RB and pan RB. Quantification was performed using electronic
scans produced from primary autoradiograms. Data were analysed
using ImageJ (http://rsbweb.nih.gov/ij/).
(TIF)
Figure S7 Impact of EIF2AK inhibition on CCT020312
signalling. A) EIF2AK2/PKR ablation fails to affect
CCT020312 mediated EIF2A phosphorylation. U2-OS
human osteosarcoma cells were transfected with 20nM siRNA
targeting PKR, or a control. Following 72 hours of RNAi cells
were treated with 10 mM CCT020312 or DMSO for the indicated
times, or with 500 mg/ml Poly (I:C). Cells were harvested and
lysates analysed by immunoblotting using antibodies as indicated.
B) EIF2AK1/HRI inhibition fails to inhibit CCT020312-
mediated EIF2A phosphorylation. U2-OS cells were treated
with 0, 40 or 80 mm of the EIF2AK1/HRI inhibitor hemin for
1 h. Hemin-containing media was replaced with media containing
10 mM CCT020312 or 200 mM sodium arsenide (AS) or DMSO.
Cells were lysed after 30 min and lysates analysed by immuno-
blotting as indicated. (B) Regulation of genes responsive to
integral stress response signalling. mRNA abundance for
CHOP/GADD153 and WARS, previously shown to depend on
stress signalling involving EIF2A phoshorylation, as determined
from cDNA data on thapsigargin and CCT020312 treated cells.
Expression values shown are relative to DMSO treated control
samples. mRNA expression data were extracted from the
microarray dataset. Normalized data are expressed as a ratio of
treated cells over untreated control cells. C) Activation of EIF2A
but not UPR selective signalling in mouse embryo
fibroblasts (MEFs). Primary MEFs were treated with 10 mM
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immunoblot using antibodies to detect markers of EIF2AK (ATF4
and CHOP) and IRE involving (XBP1s) signalling.
(TIF)
Figure S8 Absence of detectable XBP1 splicing in
CCT020312 treated human cancer cells. A) PCR based
detection of XBP1 splicing. HT29 or HCT116 cells were
treated with 10 mM CCT020312 (CCT) or 2 mM thapsigargin
(Tg) for the time indicated. Alternative splicing of XBP1 was
detected in total RNA extracts from these cells by reverse
transcription PCR. B) Detection of EIF2A phosphorylation.
Extracts for protein analysis were generated in parallel to RNA
preparations analysed for A. C) Signal quantification for
results shown in B). Charts depict background corrected P-S51
EIF2A after normalization against pan EIF2A. Signals were
quantified as for supplemental Figure 5 using Image J.
(TIF)
Figure S9 CCT020312 fails to trigger unfolded protein
response selective signalling. A) Regulation of chaper-
one encoding genes activated downstream of XBP1.
mRNA abundance for GRP94/HSP90B1 and DNAJ3/p58PK,
previously shown to rely on XBP1 signalling [7] as determined
from cDNA microarray data on thapsigargin and CCT020312
treated cells. Expression values shown are relative to DMSO
treated control samples. mRNA expression data were extracted
from the microarray dataset. Normalized data are expressed as a
ratio of treated cells over untreated control cells. (B) Regulation
of genes responsive to integral stress response signal-
ling. mRNA abundance for CHOP/GADD153 and WARS,
previously shown to depend on stress signalling involving EIF2A
phoshorylation [8], as determined from cDNA data on thapsi-
gargin and CCT020312 treated cells. Expression values shown are
relative to DMSO treated control samples. mRNA expression data
were extracted from the microarray dataset. Normalized data are
expressed as a ratio of treated cells over untreated control cells. C)
Activation of EIF2A but not UPR selective signalling in
mouse embryo fibroblasts (MEFs). Primary MEFs were
treated with 10 mM CCT020312 or 2 mM thapsigargin for
8 hours and analysed by immunoblot using antibodies to detect
markers of EIF2AK (ATF4 and CHOP) and IRE involving
(XBP1s) signalling. References. 7. Lee AH, Iwakoshi NN,
Glimcher LH (2003) XBP-1 regulates a subset of endoplasmic
reticulum resident chaperone genes in the unfolded protein
response. Mol Cell Biol 23: 7448–7459. 8. Mori K (2009)
Signalling pathways in the unfolded protein response: develop-
ment from yeast to mammals. J Biochem 146: 743–750.
(TIF)
Figure S10 Interaction of CCT020312 and paclitaxel. A,
B) Cell proliferation activity of cells following treatment with
paclitaxel, CCT020312 or the combination thereof, as determined
using a 96 hour sulphorhodamine B (SRB) colorimetric assay run
in a 96-well assay format. Agent concentrations were as indicated.
Data were used to calculate combination indices for Figure 8C.
(TIF)
Table S1 Prediction of small molecule agents connected
to the mechanism of action of CCT020312. The top ten hits
are shown. Analysis output based on cmap 02 (http://www.
broadinstitute.org/cmap/http://www.broadinstitute.org/cmap/).
(DOC)
Results S1 Assessment of hit matter.
(DOC)
Methods and Materials S1 XBP1 splicing and General
Methods for the preparation of compounds.
(DOC)
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